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OBJECTIVE — To evaluate the heterogeneity in the clinical expression in a family with
glucokinase mature-onset diabetes of the young (GCK-MODY).
RESEARCH DESIGN AND METHODS — Members (three generations) of the same
familypresentedeitherwithovertneonatalhyperglycemia,markedpostprandialhyperglycemia,
or glucosuria. Homeostasis model assessment of insulin resistance (HOMAIR) and insulinogenic
and disposition indexes were calculated. Oral glucose tolerance test (OGTT) results in the GCK
mutation carriers from this family were compared with those from other subjects with GCK
mutations in the same codon (GCK261), with other missense and other types of GCK mutations
in different codons from the European MODY Consortium database (GCKm).
RESULTS — Mutation G261R was found in the GCK gene. During the OGTT, glucose (P 
0.02) and insulin (P  0.009) response at2ha swell as at the 2-h glucose increment (GCK261
versus other missense GCK mutations, P  0.003) were signiﬁcantly higher in GCK261 than in
GCKm carriers.
CONCLUSIONS — Differing from other GCKm carriers, the glucose and insulin response to
oral glucose was signiﬁcantly higher in GCK261 carriers, indicating clinical heterogeneity in
GCK-MODY.
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I
nactivating heterozygous mutations in
the glucokinase gene (GCK) cause a
form of monogenic diabetes with auto-
somal dominant inheritance (GCK
mature-onset diabetes of the young
[MODY]) (1,2). GCK-MODY has gener-
allybeenconsideredaphenotypicallyho-
mogenous mild form of diabetes, which
doesnotleadtomarkedhyperglycemiaor
diabetescomplicationsanddoesnotneed
treatment (2–5).
Phenotypic heterogeneity within car-
riers of the same GCK mutation has been
observed only in one family (6). Here, we
report a new GCK-MODY (GCK-G261R)
family characterized by marked prandial
hyperglycemia and unusual high levels of
postprandial insulinemia.
RESEARCH DESIGN AND
METHODS— The proband (online
appendix Fig. A1, available at http://care.
diabetesjournals.org/cgi/content/full/
dc09-0681/DC1) was a ﬁrstborn child
from a Finnish family with neonatal
plasmaglucoseof10mmol/l.At2yearsof
age, without treatment, she presented
preprandial and postprandial capillary
glucose of 6.5–6.8 and 8.6 mmol/l, re-
spectively. Her younger sister had ran-
dom glucose between 7 and 11.5 mmol/l
asaneonate.Theirmotherwasdiagnosed
with gestational diabetes and treated with
insulin. After the pregnancy, she had an
A1C of 5.8% without insulin treatment,
but due to high postprandial plasma glu-
cose (10–11 mmol/l), rapid-acting meal-
time insulin was started. Since the second
pregnancy, she is treated with diet alone.
The maternal grandmother presented
with hyperglycemia and glucosuria at age
of 22 years and gestational diabetes dur-
ing four pregnancies. She was treated
with diet during the ﬁrst pregnancy and
with insulin during three later pregnan-
cies, after which she had been without
treatment. Her fasting capillary glucose
level was normally 6–7 mmol/l but
stayed at 10 mmol/l for nearly 2 weeks
after intake of larger quantities of carbo-
hydrates and returned to 6–7 mmol/l
when carbohydrates were restricted. She
takes 60 mg of nateglinide before meals.
Allavailablefamilymemberswereoffered
an oral glucose tolerance test (OGTT)
and/or genetic testing for the mutation af-
ter genetic counseling.
OGTT (except subjects 15 years)
with samples drawn at 5, 0, 30, 60, 90,
and120minwasperformedtodetermine
plasma glucose and serum insulin. Insu-
lin resistance and -cell function was es-
timated using the homeostasis model
assessment of insulin resistance
(HOMAIR) and the insulinogenic indexes
(IG30), respectively. The disposition in-
dex (DI) was used to assess -cell com-
pensation. These results and those from
15 subjects with GCK mutations in posi-
tion 261 (GCK261) from the European
MODYConsortiumDatabase(EMCD)(3)
were compared with that of carriers of
other missense and other types of GCK
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(GCKm) and normoglycemic control sub-
jectsfromtheBotniaStudy(Table1).The
studieswereapprovedbytheinstitutional
ethics committee. Written consent was
obtained from the adults and from the
parents of the children. DNA extraction,
microsatellite genotyping, direct se-
quencing, and functional analysis of the
glucokinase protein (gk), with and with-
out gk activator, were performed as de-
scribed (7–10).
RESULTS— The mutation G261R
(exon 7) on GCK was found in the pro-
band and in nine family members (aged
0.2–72 years) with abnormal fasting glu-
cose. Fasting plasma glucose ranged from
6.0to7.6mmol/l.The2-hplasmaglucose
ranged from 9.3 to 14.5 mmol/l in the
carriers, three of them presented values
exceeding 13 mmol/l. All but one of the
carriers had a 2-h increment in plasma
glucose (2hPG) higher than 3 mmol/l
and half higher than 6 mmol/l. Fasting
insulin was 4.1–9.9 mU/l and 2-h insulin
28.8–61.9 mU/l. There was no relation-
ship between age and glucose or insulin
concentrations.
The GCK261 mutation carriers from
our family, like those from the EMCD,
had a signiﬁcantly higher glucose and in-
sulin response compared with GCKm car-
riers (Table 1). Fasting plasma glucose
and insulin were similar in all groups;
however, the 2-h plasma glucose and in-
sulin and 2hPG values were signiﬁ-
cantly higher in GCK261 carriers than in
GCKm carriers (Table 1). The glucose re-
sponse during OGTT was higher at all
time points in GCK261 carriers compared
alsowithGCKmcarriers(datanotshown).
In61and35%ofGCK261carriers,2hPG
was 3 and 4.6 mmol/l, respectively.
HOMAIR, I/G30, and DI values were
higher(notsigniﬁcant)intheGCK261car-
riers (Table 1), indicating possibly higher
degree of -cell compensation (Table 1).
The results from the functional stud-
ies showed that the mutations gk-
G261R/E lead to a severely effected
protein,withanalmostnegligibleenzyme
activity, indicating that these gk mutants
cannot contribute to -cell and hepatic
glucosephosphorylation.Theeffectofthe
gkactivatorontheinactivatinggk-G261R
mutation was similar to that on the
gk-WT (see online appendix Table A1).
CONCLUSIONS — The clinical phe-
notype of carriers from our family was
heterogeneous. The proband and her sis-
ter presented with neonatal hyperglyce-
mia, their mother with gestational
diabetes, and the maternal grandmother
with glucosuria. Many carriers had much
higher2hPGvaluesthanwhatisusually
seen in GCK-MODY. In three carriers
(onechildandtwoadults),itexceeded13
mmol/l and in another young carrier 12
mmol/l, indicating no relationship be-
tweenhigh2hPGvaluesandage.Asim-
Table 1—Clinical characteristics of patients with glucokinase inactivating mutation GCK261 and functional studies of recombinant human
wild-type and mutants’ gk
GCK261:
mutations P1
Other
missense: GCK
mutations P2
Other GCK:
mutation types P3
Normal glucose
tolerance: control
subjects P4
n (male/female) 23 (13/10) 144 (73/71) 82 (42/40) 45 (20/25)
BMI (kg/m
2) 21.80 (7.0) NS 20.00 (5.42) NS 21.30 (5.73) NS 23.7 (6.2) NS
Age (years) 20.00 (27.0) NS 19.00 (27.00) NS 29.00 (28) NS 41.6 (31) 0.001
0-min plasma glucose
(mmol/l) 7.00 (0.69) NS 6.70 (0.90) NS 6.80 (1.01) 0.17 5.0 (0.7) NS
120-min plasma glucose
(mmol/l) 10.90 (4.13) 0.02 8.60 (2.58) 0.046 8.60 (2.98) 0.38 5.5 (1.8) NS
2hPG (mmol/l) 4.12 (3.25) 0.003 2.00 (2.05) 0.046 2.50 (2.20) 0.233 0.6 (1.8) 0.004
0-min plasma insulin
(mU/l) 10.00 (7.44) NS 8.00 (6.00) NS 9.00 (5.00) 0.41 7.7 (7.7) NS
120-min plasma insulin
(mU/l) 55.2 (28.05) 0.009 25.00 (23.50) 0.002 24.00 (13.50) 0.11 30.2 (27.4) 0.03
Incremental I/G30 8.71 (7.46) 0.106 6.09 (3.74) 0.513 4.21 (5.55) 0.672 23.7 (25.4) 0.003
HOMAIR 3.47 (2.31) 0.568 2.68 (2.45) 0.318 2.21 (1.92) 0.259 1.7 (1.4) 0.045
DI 3.23 (2.25) NS 2.64 (2.02) NS 1.98 (2.18) 0.76 15.5 (13.5) 0.004
Proteins
studied
Glucose S0.5
(mmol/l)
Hill number
(unit less)
ATPKm
(mmol/l)
Turnover rate
(Kcat) (sec
1)
Activity index
(AI) T-GSIR (mmol/l)
gk-WT 7.55  0.23 1.74  0.04 0.41  0.03 62.3  4.75 1.45  0.11 5
gk-G261R 68.61  16.15 1.53  0.11 0.63  0.10 17.03  4.11 0.04  0.001 7
gk-G261E 334.73  26.78 1.92  0.06 2.99  0.37 3.72  0.32 0.00 7
Upper panel: data are median (interquartile range). Clinical characteristics, glucose, and insulin values of patients with GCK-inactivating mutation GCK261, other
missense GCK-inactivating mutations, and other types of GCK-inactivating mutations (insertions, deletions, frame shifts, etc.). For insulin data: n  11 (GCK261),
36 (other missense GCK mutations), 45 (other types of GCK mutations), and 45 (normal glucose tolerant controls); P1: GCK261 mutations vs. other missense GCK
mutations; P2: GCK261 mutations vs. other types of GCK mutations; P3: other missense GCK mutations vs. other types of GCK mutations; P4: GCK261 mutations vs.
control subjects. P  0.05–0.00001 are considered statistically signiﬁcant. HOMAIR  fasting serum insulin 	 fasting serum glucose/22.5. Insulinogenic index
(I/G30)  serum insulin at 30 min  serum insulin at 0 min/serum glucose at 30 min  serum glucose at 0 min. DI  insulinogenic index/HOMAIR. Lower panel:
data are means of the three independent analyses. Results of the functional studies of gk-WT and mutants gk-G261R and gk-G261E. AI, the activity index for the
enzyme was calculated as previously described (8). Glucose S0.5 of gk-G261R mutations was carried out with 25 mmol/l of MgATP, and the ATPKm measurement
was performed at glucose concentration of 500 mmol/l. T-GSIR, threshold for glucose-stimulated insulin secretion.
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thesamemutation,whilethosewithother
GCK mutations in the MODY database
had a lower glucose response during
OGTT. Of note, a similar pattern of glu-
cose response as in GCK261 carriers has
previously been observed in GCK-L184P
carriers (6). However, while the insulin
response was attenuated in GCK-L184P
carriers, in GCK261 carriers it was high
and signiﬁcantly different from that
seen with other GCK mutations (11).
Glucokinase is required for glycogen
synthesis in liver (12). One explanation
for the high 2-h glucose in GCK261 car-
riers could be reduced hepatic glycogen
synthesis due to the lost of activity of
GCK261. Hence, the marked insulin re-
sponse could be due to larger -cell
compensation in GCK261 carriers.
Nonetheless, possible additional ge-
netic defects could be also involved.
In summary, the clinical phenotype
of patients with GCK-MODY can be het-
erogeneous and patients carrying severe
inactivatingGCKmutationscanhavehigh
postchallenge glucose values, possibly re-
sultingfromamarkedlivercomponentof
the disease.
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